Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Diabetologia · 2024
DOI: 10.1007/s00125-024-06158-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetologia, 2024. Verfasst von Roberto Trevisan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. rtrevisan@asst-pg23.it. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Insulin. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano - Bicocca.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Despite the availability of new classes of glucose-lowering drugs that improve glycaemic levels and minimise long-term complications, at least 20–25% of people with type 2 diabetes require insulin therapy. Moreover, a substantial proportion of these individuals do not achieve adequate metabolic control following insulin initiation. This is due to several factors: therapeutic inertia, fear of hypoglycaemia and/or weight gain, poor communication, complexity of insulin titration, and the number of injections needed, with the associated reduced adherence to insulin therapy. Once-weekly insulins provide a unique opportunity to simplify basal insulin therapy and to allow good glycaemic control with a low risk of hypoglycaemia. Several approaches to developing a stable and effective once-weekly insulin have been proposed, but, to date, insulin icodec and basal insulin Fc (insulin efsitora alfa) are the only two formulations for which clinical studies have been reported. The results of Phase I and II studies emphasise both efficacy (in term of glucose levels) and potential risks and adverse events. Phase III studies involving insulin icodec are reassuring regarding the risk of hypoglycaemia compared with daily basal insulin analogues. Despite some concerns raised in ongoing clinical trials, the available data suggest that weekly insulins may also be an option for individuals with type 1 diabetes, especially when adherence is suboptimal. For the first time there is an opportunity to make an important breakthrough in basal insulin therapy, particularly in people with type 2 diabetes, and to improve not only the quality of life of people with diabetes, but also the practice of diabetologists. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. rtrevisan@asst-pg23.it.
- Endocrine and Diabetology Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. rtrevisan@asst-pg23.it.
- Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy.
- Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy.
Förderung
- Università degli Studi di Milano - Bicocca
Zitieren
APA
Trevisan, R., Conti, M., & Ciardullo, S. (2024). Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. https://doi.org/10.1007/s00125-024-06158-9
Vancouver
Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. 2024. doi:10.1007/s00125-024-06158-9
BibTeX
@article{Trevisan2024,
author = {Trevisan, Roberto and Conti, Matteo and Ciardullo, Stefano},
title = {Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06158-9}
}
EUVIMED